Pain Therapeutics Announces New Publication on Alzheimer’s Disease
December 14 2017 - 8:00AM
Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company,
today announced a new publication for PTI-125, a clinical-stage
drug candidate with a novel mechanism of action for the treatment
of Alzheimer’s disease.
The new publication in Neuroimmunology and
Neuroinflammation describes an altered form of a protein called
filamin A (FLNA) that is critical to the formation of
neuropathologies associated with Alzheimer’s disease. PTI-125, a
small molecule drug, reverses these neuropathologies by selectively
binding the altered form of FLNA and restoring its normal
shape. These data, while still subject to clinical
translation, support a promising new therapeutic approach to slow
the course of Alzheimer’s disease.
The new publication can be freely accessed
online: http://nnjournal.net/article/view/2313
“This is very exciting data that we believe
supports a sound scientific rationale to continue with the clinical
evaluation of PTI-125 in Alzheimer’s disease,” said Remi Barbier,
President & CEO.
Pain Therapeutics recently announced the
completion of a successful Phase I study with PTI-125 under an
Investigational New Drug (IND) application filed with the U.S. Food
and Drug Administration (FDA). Full results of the Phase I
study were presented by Company scientists at the 10th Annual
International Conference on Clinical Trials on Alzheimer’s Disease,
in Boston, MA.
The underlying technology around PTI-125 also
supports the development of a diagnostic/biomarker to detect
Alzheimer’s disease with a simple blood test. Following a
competitive evaluation of the Pain Therapeutics’ technology for
scientific and technical merit, the NIH's National Institute on
Aging, awarded the Company a $1.8 million research grant in
September 2017 to develop a blood-based diagnostic for Alzheimer’s
disease.
About Alzheimer's
Disease and PTI-125Alzheimer’s Disease (AD) is a
progressive brain disorder that slowly destroys memory and thinking
skills, and eventually the ability to carry out the simplest
tasks. There is no approved drug therapy to slow, or even
halt, the course of AD. PTI-125 is an oral, small molecule
drug candidate that was designed in-house and characterized by
outside collaborators. PTI-125 has been shown to
significantly improve AD neuropathologies in mouse models of the
disease and in post-mortem brain tissue from AD patients, including
receptor dysfunctions, neuroinflammation, tau hyperphosphorylation,
insulin resistance and plaques and tangles that are hallmarks of
AD.
The drug development program for PTI-125 is
currently supported by research grants from the NIH. To date,
the underlying science for PTI-125 has been published in Journal of
Neuroscience, Neurobiology of Aging, Neuroimmunology and
Neuroinflammation, Journal of Biological Chemistry, PLOS-One and
other peer-reviewed scientific journals.
Pain Therapeutics owns worldwide commercial
rights to PTI-125 and related technology.
About Pain Therapeutics,
Inc.Pain Therapeutics, Inc. is a clinical-stage
biopharmaceutical company that develops novel drugs. The FDA
has not yet established the safety or efficacy of any of our drug
candidates. For more information, please visit
www.paintrials.com.
Note Regarding Forward-Looking
Statements: This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Pain Therapeutics disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such statements
include, but are not limited to, statements regarding the safety or
effectiveness of PTI-125 and the Company’s plan to continue with a
drug development plan for PTI-125. Such statements are based on
management's current expectations, but actual results may differ
materially due to various factors. Such statements involve
risks and uncertainties, including, but not limited to, those risks
and uncertainties relating to the ability to demonstrate the
safety, efficacy or potential health benefits of PTI-125 in humans
and to determine which patient, or subpopulation of patients, may
benefit from treatment. For further information regarding
these and other risks related to our business, investors should
consult our filings with the U.S. Securities and Exchange
Commission.
For More Information
Contact:Ruth ArayaPain Therapeutics,
Inc.IR@paintrials.com(512) 501-2485
Pain Therapeutics (NASDAQ:PTIE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pain Therapeutics (NASDAQ:PTIE)
Historical Stock Chart
From Sep 2023 to Sep 2024